356 related articles for article (PubMed ID: 26015511)
1. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
[TBL] [Abstract][Full Text] [Related]
2. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
3. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
4. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
[TBL] [Abstract][Full Text] [Related]
5. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
6. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
Wynes MW; Hinz TK; Gao D; Martini M; Marek LA; Ware KE; Edwards MG; Böhm D; Perner S; Helfrich BA; Dziadziuszko R; Jassem J; Wojtylak S; Sejda A; Gozgit JM; Bunn PA; Camidge DR; Tan AC; Hirsch FR; Heasley LE
Clin Cancer Res; 2014 Jun; 20(12):3299-309. PubMed ID: 24771645
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.
Göke F; Göke A; von Mässenhausen A; Franzen A; Sharma R; Kirsten R; Böhm D; Kristiansen G; Stenzinger A; Wynes M; Hirsch FR; Weichert W; Heasley L; Buettner R; Perner S
Digestion; 2013; 88(3):172-81. PubMed ID: 24135816
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.
Clauditz TS; Böttcher A; Hanken H; Borgmann K; Sauter G; Wilczak W; Grob T; Münscher A
J Cancer Res Clin Oncol; 2018 Jan; 144(1):53-61. PubMed ID: 29022097
[TBL] [Abstract][Full Text] [Related]
9. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
10. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
[TBL] [Abstract][Full Text] [Related]
11. Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Lin CL; Chiang WF; Tung CL; Hsieh JL; Hsiao JR; Huang WT; Feng LY; Chang CH; Liu SY; Tsao CJ; Feng YH
Mol Med Rep; 2015 Jan; 11(1):547-54. PubMed ID: 25333206
[TBL] [Abstract][Full Text] [Related]
12. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
[TBL] [Abstract][Full Text] [Related]
13. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1.
Nguyen PT; Tsunematsu T; Yanagisawa S; Kudo Y; Miyauchi M; Kamata N; Takata T
Br J Cancer; 2013 Oct; 109(8):2248-58. PubMed ID: 24045665
[TBL] [Abstract][Full Text] [Related]
14. Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis.
Sahores A; May M; Sequeira GR; Fuentes C; Jacobsen B; Lanari C; Lamb CA
Curr Cancer Drug Targets; 2018; 18(10):979-987. PubMed ID: 29237381
[TBL] [Abstract][Full Text] [Related]
15. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.
Marshall ME; Hinz TK; Kono SA; Singleton KR; Bichon B; Ware KE; Marek L; Frederick BA; Raben D; Heasley LE
Clin Cancer Res; 2011 Aug; 17(15):5016-25. PubMed ID: 21673064
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
Stanam A; Gibson-Corley KN; Love-Homan L; Ihejirika N; Simons AL
Oncotarget; 2016 Nov; 7(46):76087-76100. PubMed ID: 27738319
[TBL] [Abstract][Full Text] [Related]
19. Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro.
Brands RC; Knierim LM; De Donno F; Steinacker V; Hartmann S; Seher A; Kübler AC; Müller-Richter UDA
Oncol Rep; 2017 Sep; 38(3):1877-1885. PubMed ID: 28714017
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.
Weeden CE; Holik AZ; Young RJ; Ma SB; Garnier JM; Fox SB; Antippa P; Irving LB; Steinfort DP; Wright GM; Russell PA; Ritchie ME; Burns CJ; Solomon B; Asselin-Labat ML
Mol Cancer Ther; 2017 Aug; 16(8):1610-1622. PubMed ID: 28611104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
